AKTX (Akari Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


AKTX Akari Therapeutics PLC AKTX
32 GF Score
Price $12.94
View Full Analysis

What is Akari Therapeutics FCF Margin %?

Akari Therapeutics AKTX -7.39% 32 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates AKTX with a GF Score™ of 32/100. Among 948 Biotechnology companies, Akari Therapeutics ranks worse than 105485.13% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Akari Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-2.49 Mil. Akari Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Akari Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Akari Therapeutics's current FCF Yield % is -47.35%.

The historical rank and industry rank for Akari Therapeutics's FCF Margin % or its related term are showing as below:


AKTX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28
* Ranked among companies with meaningful FCF Margin % only.

Akari Therapeutics FCF Margin % Related Terms

Akari Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics FCF Margin % Chart

Akari Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Akari Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AKTX vs MBRX, JAGX, ANEB: FCF Margin % Comparison

For the Biotechnology subindustry, Akari Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akari Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's FCF Margin % falls into.


AKTX
32GF Score
Akari Therapeutics PLC AKTX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Akari Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-10.568/0
= %

Akari Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.488/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Akari Therapeutics (AKTX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Akari Therapeutics and its competitors. According to the industry distribution chart, Akari Therapeutics ranks #999999 out of 948 companies in the Biotechnology industry.
Is Akari Therapeutics' FCF Margin % too high?
Akari Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Akari Therapeutics ranks #999999 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' FCF Margin % compare to MBRX and JAGX?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #999999 out of 948 companies for FCF Margin %. This places Akari Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for AKTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.94
Price